BD to Expand its Manufacturing Site in Columbus, USA
Introduction:
BD (Becton, Dickinson and Company) has announced plans to invest US$110 million to expand production of prefillable syringes at its manufacturing site in Columbus.
Features:
The investment involves the establishment of production lines for glass prefillable syringes at the Columbus, Nebraska site.
Manufacturing will include 1 mL and 2.25 mL glass prefillable syringe formats.
The syringes are intended for use in biologic and GLP-1 drug delivery.
The syringe platform is designed to accommodate high-viscosity formulations.
Production systems will support the manufacture of glass prefillable syringe components.
The development includes the installation of equipment for glass syringe manufacturing.
Manufacturing processes will support the production of syringe components used in combination drug products.
Operations will support integration with autoinjector drug-delivery devices. Production lines will support large-scale manufacturing of prefillable syringe systems.
Manufacturing operations will include upgrades to existing production lines at the site. Additional production capacity will be added for syringe manufacturing.
Production from the new syringe lines is expected to begin in mid-2026.
Specifications:
| Name | BD (Becton, Dickinson and Company) |
| Type | New Construction |
| Budget | US$110 million |
| Year | 2026 |
